Hepatitis B Virus Reactivation Following Salazosulfapyridine Monotherapy in a Patient with Rheumatoid Arthritis.

Abstract

A 72-year-old man was diagnosed with rheumatoid arthritis (RA) and prior hepatitis B virus (HBV) infection. He began treatment with salazosulfapyridine (SASP). Several months later, his blood tests reflected a slightly elevated liver function. Serum tests were positive for hepatitis B surface antigen and HBV-DNA, and the diagnosis of de novo HBV hepatitis was made. A genetic analysis showed that he had polymorphisms of ABCG2 and NAT2, which could lead to high plasma concentrations of SASP and sulfapyridine. To the best of our knowledge, this is the first report of de novo hepatitis developing during SASP monotherapy for RA.

• Authors: Kengo Akashi, Jun Saegusa, Yuji Nakamachi, Takashi Nakazawa, Shunichi Kumagai, Akio Morinobu
• Journal: Internal medicine (Tokyo, Japan) (Intern Med) Vol. 55 Issue 10 Pg. 1371-3 ( 2016) ISSN: 1349-7235 [Electronic] Japan
• PMID: 27181550 (Publication Type: Case Reports, Journal Article)

Chemical References

• Antirheumatic Agents
• DNA, Viral
• Hepatitis B Surface Antigens
• Sulfasalazine

Topics

• Aged
• Antirheumatic Agents (adverse effects, therapeutic use)
• Arthritis, Rheumatoid (drug therapy)
• DNA, Viral
• Hepatitis B (immunology)
• Hepatitis B Surface Antigens (blood)
• Hepatitis B virus (drug effects)
• Humans
• Male
• Sulfasalazine (adverse effects, therapeutic use)
• Virus Activation (drug effects)